Moderna, a biotech company developing messenger RNA (mRNA) therapeutics, has revealed a revised agreement to supply 20 million doses of its Covid-19 vaccines and updated booster candidates to Korea in 2022.

Under the new accord, the company will provide 15 million doses for delivery in the third quarter of 2022 and five million doses in the fourth quarter to the Korean government.

The company recently disclosed its study results of neutralizing antibodies against the analysis of neutralizing antibodies generated by the booster vaccine candidates against Covid-19 variants of concern.

When 50 micrograms of Moderna's mRNA vaccine were administered to people, the neutralizing antibody against the Omicron variant increased about 37 times compared to unvaccinated status. Also, a dose of 100 micrograms increased the neutralizing antibody by about 83 times.

However, Moderna said it was waiting for the Korean government's authorization.

"We thank the government of Korea for their planning ahead for the fall 2022 booster season with this supply agreement for our mRNA Covid-19 vaccine and booster," Moderna CEO Stephane Bancel said. "We remain committed to helping to end the Covid-19 pandemic."

Moderna Korea recently received approval from the Ministry of Food and Drug Safety for its Spikevax mRNA-1273, a Covid-19 mRNA vaccine agreed to be manufactured by Samsung Biologics this month.

The recent regulatory authorization granted official qualification for Moderna's mRNA vaccine produced at a Korea-based pharmaceutical plant sold in Korea and overseas.